117 related articles for article (PubMed ID: 31689237)
1. Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway.
Shen J; Zhou Y; Zhang X; Peng W; Peng C; Zhou Q; Li C; Wen T; Shi Y
Aging (Albany NY); 2019 Nov; 11(21):9280-9294. PubMed ID: 31689237
[TBL] [Abstract][Full Text] [Related]
2. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
3. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
[TBL] [Abstract][Full Text] [Related]
4. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
5. USP10 promotes intrahepatic cholangiocarcinoma cell survival and stemness via SNAI1 deubiquitination.
Zhu W; Ye B; Yang S; Li Y
J Mol Histol; 2023 Dec; 54(6):703-714. PubMed ID: 37755617
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
7. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.
Affo S; Nair A; Brundu F; Ravichandra A; Bhattacharjee S; Matsuda M; Chin L; Filliol A; Wen W; Song X; Decker A; Worley J; Caviglia JM; Yu L; Yin D; Saito Y; Savage T; Wells RG; Mack M; Zender L; Arpaia N; Remotti HE; Rabadan R; Sims P; Leblond AL; Weber A; Riener MO; Stockwell BR; Gaublomme J; Llovet JM; Kalluri R; Michalopoulos GK; Seki E; Sia D; Chen X; Califano A; Schwabe RF
Cancer Cell; 2021 Jun; 39(6):866-882.e11. PubMed ID: 33930309
[TBL] [Abstract][Full Text] [Related]
8. Diacylglycerol kinase alpha is a proliferation marker of intrahepatic cholangiocarcinoma associated with the prognosis.
Shichi S; Sugiyama K; Asahi Y; Shirakawa C; Nakamoto H; Kimura S; Wakizaka K; Aiyama T; Nagatsu A; Orimo T; Kakisaka T; Taketomi A
Cancer Med; 2024 May; 13(9):e7238. PubMed ID: 38716625
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract][Full Text] [Related]
10. DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
Fukushima NM; Adachi T; Tanaka T; Matsushima H; Imamura H; Hara T; Soyama A; Hidaka M; Kanetaka K; Eguchi S
Anticancer Res; 2024 Jun; 44(6):2417-2424. PubMed ID: 38821583
[TBL] [Abstract][Full Text] [Related]
11. Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting β-catenin signaling pathway.
Yu W; Zeng F; Xiao Y; Chen L; Qu H; Hong J; Qu C; Cheng G
Chem Biol Interact; 2024 Jan; 387():110816. PubMed ID: 38000456
[TBL] [Abstract][Full Text] [Related]
12. CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma.
Liu S; Wang Y; Wang T; Shi K; Fan S; Li C; Chen R; Wang J; Jiang W; Zhang Y; Chen Y; Xu X; Yu Y; Li C; Li X
Mol Cancer; 2024 Feb; 23(1):35. PubMed ID: 38365721
[TBL] [Abstract][Full Text] [Related]
13. VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
Xu H; Lin X; Li Z; He X; Li Y; Qiu L; Lu L; Liu B; Zhan M; He K
J Gastroenterol; 2023 Sep; 58(9):925-944. PubMed ID: 37391589
[TBL] [Abstract][Full Text] [Related]
14. Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a.
Zhu X; Bao W; Xie X; Chen B; Li R; Zhao J; Wu L; Yu Z; Li S; Zhu Q; Chen G; Li J
Mol Carcinog; 2024 Apr; 63(4):772-784. PubMed ID: 38289159
[TBL] [Abstract][Full Text] [Related]
15. m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4/β-catenin signaling pathway.
Xiang D; Gu M; Liu J; Dong W; Yang Z; Wang K; Fu J; Wang H
Cancer Lett; 2023 Apr; 560():216144. PubMed ID: 36958694
[TBL] [Abstract][Full Text] [Related]
16. Modulating PCGF4/BMI1 Stability Is an Efficient Metastasis-Regulatory Strategy Used by Distinct Subtypes of Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma.
Hu J; Xu H; Ma X; Bai M; Zhou Y; Miao R; Wang F; Li X; Cheng B
Am J Pathol; 2024 Jul; 194(7):1388-1404. PubMed ID: 38670529
[TBL] [Abstract][Full Text] [Related]
17. CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m
Zhou S; Yang K; Chen S; Lian G; Huang Y; Yao H; Zhao Y; Huang K; Yin D; Lin H; Li Y
J Transl Med; 2023 Jan; 21(1):43. PubMed ID: 36691046
[TBL] [Abstract][Full Text] [Related]
18. TRIM29 facilitates proliferation and malignancy of cholangiocarcinoma cells by activating MAPK and β-catenin pathways.
Yang J; Bao W; Diao H; Yang S; Qiu L; Xu C; Zhao B
Environ Toxicol; 2023 Aug; 38(8):2002-2010. PubMed ID: 37219039
[TBL] [Abstract][Full Text] [Related]
19. IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway.
Zhou M; Yu H; Bai M; Lu S; Wang C; Ke S; Huang J; Li Z; Xu Y; Yin B; Li X; Feng Z; Fu Y; Jiang H; Ma Y
Cancer Sci; 2024 Mar; 115(3):777-790. PubMed ID: 38228495
[TBL] [Abstract][Full Text] [Related]
20. MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing.
Huang T; Cao H; Liu C; Sun X; Dai S; Liu L; Wang Y; Guo C; Wang X; Gao Y; Tang W; Xia Y
Cell Death Dis; 2024 Jun; 15(6):411. PubMed ID: 38866777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
